FibroBiologics (FibroBiologics) Ending Cash Position : $8.16 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Ending Cash Position?

FibroBiologics's Ending Cash Position for the quarter that ended in Mar. 2024 was $8.16 Mil.

FibroBiologics's quarterly Ending Cash Position declined from Sep. 2023 ($10.77 Mil) to Dec. 2023 ($9.16 Mil) and declined from Dec. 2023 ($9.16 Mil) to Mar. 2024 ($8.16 Mil).

FibroBiologics's annual Ending Cash Position increased from Dec. 2021 ($0.41 Mil) to Dec. 2022 ($2.27 Mil) and increased from Dec. 2022 ($2.27 Mil) to Dec. 2023 ($9.16 Mil).

FibroBiologics Ending Cash Position Historical Data

The historical data trend for FibroBiologics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Ending Cash Position Chart

FibroBiologics Annual Data

Trend

Dec21

Dec22

Dec23

Ending Cash Position

0.41

2.27

9.16

FibroBiologics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial				14.74	11.38	10.77	9.16	8.16

FibroBiologics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

FibroBiologics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.266	+	6.897
	=	9.16

FibroBiologics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	9.163	+	-1.005
	=	8.16

FibroBiologics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics (FibroBiologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SG0:Germany

Address

455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598

Website

https://www.fibrobiologics.com

FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines

From GuruFocus

FibroBiologics Announces Three Japanese Patents on Fibroblast Technology

By PRNewswire • 02-12-2024

FibroBiologics Announces Three United States Patents for Fibroblast Technology

By PRNewswire • 02-12-2024